Sleep‐wake abnormalities in patients with cirrhosis

Sara Montagnese, Cristiano De Pittà, Michele De Rui, Michela Corrias, Matteo Turco, Carlo Merkel, Piero Amodio, Rodolfo Costa, Debra J. Skene, Angelo Gatta – 6 June 2013 – A considerable proportion of patients with cirrhosis exhibit insomnia, delayed sleep habits, and excessive daytime sleepiness. These have been variously attributed to hepatic encephalopathy and impaired hepatic melatonin metabolism, but the understanding of their pathophysiology remains limited and their treatment problematic. Sleep is regulated by the interaction of a homeostatic and a circadian process.

Identification of veno‐occlusive regions in a right liver graft after reconstruction of vein segments 5 and 8: Application of indocyanine green fluorescence imaging

Yoshikuni Kawaguchi, Yasuhiko Sugawara, Takeaki Ishizawa, Shouichi Satou, Junichi Kaneko, Sumihito Tamura, Taku Aoki, Yoshihiro Sakamoto, Kiyoshi Hasegawa, Norihiro Kokudo – 3 June 2013

CD73 (ecto‐5′‐nucleotidase) hepatocyte levels differ across mouse strains and contribute to mallory‐denk body formation

Natasha T. Snider, Nicholas W. Griggs, Amika Singla, David S. Moons, Sujith V.W. Weerasinghe, Anna S. Lok, Chunhai Ruan, Charles F. Burant, Hari S. Conjeevaram, M. Bishr Omary – 31 May 2013 – Formation of hepatocyte Mallory‐Denk bodies (MDBs), which are aggregates of keratins 8 and 18 (K8/K18), ubiquitin, and the ubiquitin‐binding protein, p62, has a genetic predisposition component in humans and mice. We tested the hypothesis that metabolomic profiling of MDB‐susceptible C57BL and MDB‐resistant C3H mouse strains can illuminate MDB‐associated pathways.

Neutralization resistance of hepatitis C virus can be overcome by recombinant human monoclonal antibodies

Jannie Pedersen, Thomas H.R. Carlsen, Jannick Prentoe, Santseharay Ramirez, Tanja B. Jensen, Xavier Forns, Harvey Alter, Steven K.H. Foung, Mansun Law, Judith Gottwein, Nina Weis, Jens Bukh – 31 May 2013 – Immunotherapy and vaccine development for hepatitis C virus (HCV) will depend on broadly reactive neutralizing antibodies (NAbs). However, studies in infectious strain JFH1‐based culture systems expressing patient‐derived Core‐NS2 proteins have suggested neutralization resistance for specific HCV strains, in particular, of genotype 2.

Identification of driver genes in hepatocellular carcinoma by exome sequencing

Sean P. Cleary, William R. Jeck, Xiaobei Zhao, Kui Chen, Sara R. Selitsky, Gleb L. Savich, Ting‐Xu Tan, Michael C. Wu, Gad Getz, Michael S. Lawrence, Joel S. Parker, Jinyu Li, Scott Powers, Hyeja Kim, Sandra Fischer, Maha Guindi, Anand Ghanekar, Derek Y. Chiang – 31 May 2013 – Genetic alterations in specific driver genes lead to disruption of cellular pathways and are critical events in the instigation and progression of hepatocellular carcinoma (HCC). As a prerequisite for individualized cancer treatment, we sought to characterize the landscape of recurrent somatic mutations in HCC.

Perturbation of MicroRNA‐370/Lin‐28 homolog A/nuclear factor kappa B regulatory circuit contributes to the development of hepatocellular carcinoma

Wen‐Ping Xu, Min Yi, Qian‐Qian Li, Wei‐Ping Zhou, Wen‐Ming Cong, Yuan Yang, Bei‐Fang Ning, Chuan Yin, Zhao‐Wei Huang, Jian Wang, Hui Qian, Cai‐Feng Jiang, Yue‐Xiang Chen, Chun‐Yan Xia, Hong‐Yang Wang, Xin Zhang, Wei‐Fen Xie – 31 May 2013 – MicroRNA 370 (miR‐370) is located within the DLK1/DIO3 imprinting region on human chromosome 14, which has been identified as a cancer‐associated genomic region. However, the role of miR‐370 in malignances remains controversial. Here, we report that miR‐370 was repressed in human hepatocellular carcinoma (HCC) tissues and hepatoma cell lines.

Subscribe to